• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Delcath touts 500th commercial Chemosat treatment in Europe

February 2, 2018 By Sarah Faulkner

Delcath SystemsDelcath Systems (NSDQ:DCTH) said today that doctors in Europe performed the 500th percutaneous hepatic perfusion therapy treatment using Delcath’s Chemosat delivery system.

The drug-device combo has been available in certain European markets since 2012.

“This is a meaningful milestone for Delcath, one that speaks to the belief physicians in Europe have developed in our product and this therapy for certain types of liver cancers. Our commercialization efforts in Europe have established a considerable body of published and presented research data that demonstrates the safety and efficacy of this therapy in appropriate patients,” president & CEO Jennifer Simpson said in prepared remarks.

“Further, Dutch Health Authorities recently included Chemosat treatment in their published guidelines for ocular melanoma liver metastases, a step toward potential reimbursement coverage of Chemosat in the Dutch market. We continue to leverage this experience to validate the safety and efficacy of the melphalan/Hepatic Delivery System (Chemosat) in our clinical trials.”

The company is evaluating its liver cancer therapy in Phase III trials in the U.S. in the hopes of winning FDA approval.

Delcath pulled the trigger on a 1-for-350 reverse stock split late last year, which reduced the number of issued and outstanding shares of the company’s common stock from 490 million to 1.4 million shares.

In September, Delcath and a group of investors made an end run around the company’s shareholders with a deal that paved the way for the reverse split that stockowners have twice shot down.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Delcath Systems Inc.

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS